Screener
Indivior Pharmaceuticals, Inc. INDV Business Segments — Gain (Loss) on Extinguishment of Debt
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainsLossesOnExtinguishmentOfDebt.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Other (income) and expenses: | ||
| Interest (income) | (3) | (4) |
| Interest expense | 7 | 12 |
| Loss on debt extinguishment | 18 | — |
| Income before income taxes | 115 | 59 |
| Income tax expense | 26 | 11 |
| Net income | $89 | $47 |
| *Total SUBLOCADE net revenue | $232 | $176 |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s business segments — gain (loss) on extinguishment of debt?
- Indivior Pharmaceuticals, Inc. (INDV) reported business segments — gain (loss) on extinguishment of debt of -$18M in Q1 2026.
- What does business segments — gain (loss) on extinguishment of debt mean?
- Captures the financial impact of retiring debt obligations before their scheduled maturity date, including premiums or discounts paid. This metric reflects the results of capital structure management and debt refinancing activities.
Ask your AI about Indivior Pharmaceuticals, Inc.'s business segments — gain (loss) on extinguishment of debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude